AstraZeneca PLC vs Wipro Limited: Strategic Comparison

This in-depth comparison examines AstraZeneca PLC and Wipro Limited across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AstraZeneca PLC on its own, evaluating Wipro Limited, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AstraZeneca PLC and Wipro Limited is widest.

On the headline numbers, AstraZeneca PLC reports annual revenue of $58.7B against ~$10.7B for Wipro Limited, while their respective market capitalizations stand at $254.6B and $28.0B. AstraZeneca PLC is headquartered in United Kingdom and Wipro Limited in India, and those different home markets shape how each company competes.

AstraZeneca PLC: AstraZeneca is a British-Swedish biopharmaceutical company best known to the public for the COVID-19 vaccine it developed with the University of Oxford, but most of its revenue comes from medicines for cancer, cardiovascular and metabolic disease, respiratory and immune conditions, and rare diseases. It is headquartered on the Cambridge Biomedical Campus in England and runs strategic research centres in the UK, Sweden, the United States and China; the Beijing centre announced in March 2025 was its sixth.

Wipro Limited: Wipro is one of India's largest IT services companies. It reported about $10.48 billion of IT services revenue in FY2026. Srini Pallia has been CEO since April 2024, and the Premji family remains the controlling shareholder.

AstraZeneca PLC and Wipro Limited pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AstraZeneca PLC and Wipro Limited.

AstraZeneca PLC business model: AstraZeneca discovers, develops and sells prescription medicines, and the economics turn on patent-protected pricing funded by heavy research spending. It invested $14.2 billion in research and development in 2025, about a quarter of Total Revenue, and reported gross profit of $48.1 billion on cost of sales of $10.6 billion. Because most drug candidates fail, the company supplements internal discovery with licensing and acquisitions, from the $39 billion Alexion deal to the Daiichi Sankyo antibody-drug conjugate alliance, and shares development costs and profits with partners including Daiichi Sankyo, Amgen and Merck.

Wipro Limited business model: Wipro earns most of its revenue from its IT services segment: multi-year contracts to build, run, and modernize enterprise software and infrastructure, plus consulting, cloud migration, cybersecurity, engineering services, and business process work. Contracts are priced as time-and-materials, fixed-price, or managed-service deals. Sales are organized into four strategic market units (Americas 1, Americas 2, Europe, and APMEA), and banking, financial services, and insurance is its largest industry vertical. Delivery relies on large engineering teams in India working with onshore and nearshore staff. Acquisitions such as Capco (financial services consulting) and Rizing (SAP consulting) were meant to add higher-value advisory work on top of that delivery base.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AstraZeneca PLC stack up against those of Wipro Limited.

AstraZeneca PLC competitive advantage: AstraZeneca's main advantage is the depth of its oncology portfolio and the Phase III evidence behind it. Tagrisso, Imfinzi, Enhertu, Lynparza and Calquence each rest on trials that changed treatment practice, and the company had more than 100 Phase III studies running at the end of 2025 after 16 positive Phase III readouts during the year. Scale matters too: $58.7 billion of Total Revenue and $14.2 billion of annual R&D spending let it fund late-stage trials that smaller biotechs cannot, which is why partners such as Daiichi Sankyo and Amgen co-develop medicines with it. Its commercial reach in emerging markets, where China alone is about 12% of revenue, is wider than that of most US-based rivals.

Wipro Limited competitive advantage: Wipro's strengths are long-standing client relationships, a large India delivery base, engineering services depth, Capco's position in financial services consulting, a net cash balance sheet, and stable Premji family control.

Future prospects matter as much as current results. The growth strategies below explain how AstraZeneca PLC and Wipro Limited each plan to expand from here.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.

Wipro Limited growth strategy: Under Srini Pallia, Wipro is focusing on large deals, consulting-led selling, AI-enabled delivery through its ai360 program, and growth in its biggest client accounts. In 2025 it agreed to acquire Harman's Digital Transformation Solutions unit to add engineering services capacity.

A closer look at the financial trajectory of AstraZeneca PLC and Wipro Limited rounds out the comparison.

AstraZeneca PLC: AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021.

Wipro Limited: In FY2026 Wipro reported gross revenue of Rs 926.2 billion and net income of Rs 132.0 billion. IT services revenue was about $10.48 billion, roughly level with the year before, and the IT services operating margin was 17.2%. Fourth-quarter gross revenue was Rs 242.4 billion, up 7.7% year over year, and quarterly net income was Rs 35.0 billion, down 1.9%. With the Q4 results in April 2026, the board approved a Rs 150 billion share buyback. In Q1 FY2027, gross revenue rose 10.6% year over year to Rs 244.8 billion. IT services revenue fell 1.4% sequentially to $2,614.5 million, and net income was Rs 33.6 billion ($354.6 million), up 0.6% year over year.